Company / Cost of Revenue
Cytek Biosciences, Inc. Cost of Revenue History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$97.0M
FY2025
5-year range
$41.1M / $97.0M
FY2021-FY2025
Trend
+8.6%
vs FY2024
Sector context
#92 of 113
Health Care
What the data says
Cytek Biosciences, Inc.'s cost of revenue of $97M is lower than 81% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 4 consecutive years, from $41M in FY2021 to $97M in FY2025.
Based on SEC 10-K filings.
$97M in FY2025 with a 5-year CAGR of +18.7%.
Increased from $84M to $97M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +15.4%
- 5-Year CAGR
- +18.7%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 113This company $97.0M Sector average $11.3B
▼
-99.1% below sector average
Key checks
Key Insights
- Cytek Biosciences, Inc.'s cost of revenue has grown for 4 consecutive years.
- 5-year CAGR of +18.7%, indicating consistent growth.
- In FY2025, cost of revenue increased 8.6% year-over-year.
- Ranks #92 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $97.0M | +8.6% |
| FY2024 | $89.3M | +6.9% |
| FY2023 | $83.6M | +32.6% |
| FY2022 | $63.1M | +53.3% |
| FY2021 | $41.1M | +0.0% |
| FY2020 | $41.1M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026